ZYME - Zymeworks Inc.

NYSE - NYSE Delayed Price. Currency in USD
14.10
-0.83 (-5.56%)
At close: 4:02PM EST
Stock chart is not supported by your current browser
Previous Close14.93
Open14.67
Bid0.00 x 1300
Ask0.00 x 900
Day's Range14.06 - 14.67
52 Week Range7.26 - 29.00
Volume182,479
Avg. Volume117,290
Market Cap451.021M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.48
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.88
Trade prices are not sourced from all markets
  • Business Wire7 days ago

    Zymeworks Submits Investigational New Drug (IND) Application for ZW49 and Presents IND-Enabling Studies at the San Antonio Breast Cancer Symposium

    VANCOUVER, Canada-- -- ZW49 combines Azymetric™ and ZymeLink™ technologies to broaden the therapeutic window of antibody-drug conjugates Complete tumor regressions observed in high and low HER2-expressing models Superior preclinical efficacy compared to approved HER2 ADCs Toxicology results support clinical dosing well above predicted efficacy levels Potential to address unmet need in high and low ...

  • Reuters18 days ago

    BRIEF-Zymeworks, Beigene Announce License And Collaboration Agreement For Zymeworks' Her2-Targeted Therapeutic Candidates

    Nov 27 (Reuters) - Beigene Ltd: * ZYMEWORKS AND BEIGENE ANNOUNCE LICENSE AND COLLABORATION AGREEMENT FOR ZYMEWORKS’ HER2-TARGETED THERAPEUTIC CANDIDATES, ZW25 AND ZW49, IN ASIA-PACIFIC AND RESEARCH AND ...

  • Business Wire18 days ago

    Zymeworks and BeiGene Announce License and Collaboration Agreement for Zymeworks’ HER2-Targeted Therapeutic Candidates, ZW25 and ZW49, in Asia-Pacific and Research and License Agreement for Zymeworks’ Azymetric™ and EFECT™ Platforms Globally

    BeiGene acquires exclusive development and commercial rights to Zymeworks’ bispecific candidates, ZW25 and ZW49, in Asia (excluding Japan), Australia, and New Zealand. The companies will collaborate on joint global development for selected indications. BeiGene also acquires licenses for Zymeworks’ Azymetric™ and EFECT™ platforms to develop and commercialize up to three bispecific antibody therapeutics globally directed to BeiGene's targets.

  • Business Wirelast month

    Zymeworks Announces Updated Clinical Data for Novel Bispecific Antibody, ZW25, Presented at the EORTC-NCI-AACR Symposium

    DUBLIN-- -- ZW25 Active and Well Tolerated Across Multiple HER2-expressing Tumor Types Durable Anti-Tumor Activity with Confirmed Partial Responses and Median Progression-Free Survival > Six Months 82 Percent of Heavily Pretreated Patients Experienced Disease Control Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional therapeutics, announced today the plenary ...

  • GlobeNewswirelast month

    Recent Analysis Shows Cleveland-Cliffs, Optical Cable, Camtek, QIAGEN N.V, Value Line, and Zymeworks Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, Nov. 13, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Business Wirelast month

    Zymeworks to Present at Upcoming Investor Conferences

    Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming Stifel 2018 Healthcare Conference taking place November 13-14, 2018 in New York, NY and at the Jefferies 2018 London Healthcare Conference taking place November 14-15, 2018 in London, England.

  • Zymeworks Inc. (ZYME) Reports Q3 Loss, Tops Revenue Estimates
    Zackslast month

    Zymeworks Inc. (ZYME) Reports Q3 Loss, Tops Revenue Estimates

    Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 6.35% and 2.70%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Business Wirelast month

    Zymeworks Reports Financial Results for the Third Quarter of 2018

    Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the third quarter ended September 30, 2018.

  • Business Wire2 months ago

    Zymeworks Announces Selection of ZW25 Abstract for Plenary Session Presentation at the 30th EORTC-NCI-AACR Symposium

    VANCOUVER, British Columbia-- -- Results from Phase 1 trial highlight ZW25’s single agent effect in HER2-driven cancers New and updated data focus on gastroesophageal and other HER2-expressing cancers Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional therapeutics, announced today that its abstract describing new data from the Company’s adaptive Phase 1 clinical ...

  • Business Wire2 months ago

    Zymeworks and LEO Pharma Enter into Bispecific Antibody Licensing and Research Collaboration

    Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, and LEO Pharma A/S, a global leader in medical dermatology, have entered into a licensing and research collaboration to discover and develop bispecific antibodies targeting cytokine-receptor pathways using Zymeworks’ antibody discovery capabilities and its proprietary Azymetric™ and EFECT™ platforms. LEO Pharma will have exclusive rights to further develop and commercialize two bispecific candidates in dermatology indications, while Zymeworks retains rights to develop antibodies in all other therapeutic areas.

  • Business Wire2 months ago

    Zymeworks to Webcast R&D Briefing

    Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it will webcast its R&D Briefing from 9:00 a.m. to 12:00 p.m. Eastern Time on Thursday, October 11, 2018 in New York City. Zymeworks’ management team will discuss the Company’s clinical strategy for ZW25, provide an update on its next clinical compound ZW49, and highlight its early-stage platforms and technologies. Mark Pegram, MD, is the Susy Yuan-Huey Hung Professor of Medicine (Oncology) at the Stanford University Medical Center, Director of the Stanford Cancer Institute's Breast Oncology Program, Associate Director of Clinical Research, and Associate Dean of Clinical Research Quality.

  • Business Wire3 months ago

    Zymeworks to Present at Ladenburg Thalmann 2018 Healthcare Conference

    Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming Ladenburg Thalmann 2018 Healthcare Conference taking place October 1-2, 2018 in New York, NY.

  • Business Wire3 months ago

    Zymeworks Names Anthony Polverino, Ph.D., Executive Vice President of Early Development and Chief Scientific Officer

    Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced it has named Anthony (Tony) Polverino, Ph.D., Executive Vice President of Early Development and Chief Scientific Officer. In his new role, Dr. Polverino will be instrumental in setting and driving Zymeworks’ R&D strategy.

  • Business Wire3 months ago

    Zymeworks Reports IND-Submission Milestone Achieved in Lilly Collaboration

    Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported the achievement of a development milestone in its collaboration with Eli Lilly and Company. In accordance with Zymeworks’ 2013 licensing and collaboration agreement with Lilly, Zymeworks will receive a milestone payment of US$2.0 million for Lilly’s submission of an IND application for a bispecific antibody enabled by Zymeworks’ proprietary Azymetric™ platform. Previously, Zymeworks announced Lilly’s nomination of two bispecific immuno-oncology drug candidates for late-stage preclinical development.

  • Business Wire4 months ago

    Zymeworks to Present at Wells Fargo Healthcare Conference

    Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming 13th Annual Wells Fargo Securities Healthcare Conference taking place September 5-6, 2018 in Boston, MA.

  • Business Wire4 months ago

    Zymeworks to Present at Canaccord Genuity 38th Annual Growth Conference

    Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming Canaccord Genuity 38th Annual Growth Conference taking place August 8-9, 2018 in Boston, MA, USA.

  • Business Wire4 months ago

    Zymeworks Reports Financial Results for the Second Quarter of 2018

    Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the second quarter ended June 30, 2018.

  • Business Wire6 months ago

    Zymeworks Closes Previously Announced Public Offering

    Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, announced today that it has closed its previously announced underwritten public offering (the “Offering”) of 6,210,000 common shares, including the underwriters’ full exercise of their over-allotment option to purchase 810,000 additional shares, at a price to the public of US$15.75 per common share, for aggregate gross proceeds to the Company of approximately US$97.8 million, before deducting the underwriting discounts and commissions and estimated Offering expenses.

  • Business Wire6 months ago

    Zymeworks Announces Election of Directors and Voting Results from Shareholder Meeting

    Zymeworks Inc. , a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, is pleased to announce the detailed voting results on the items of business considered at its Annual General and Special Meeting of Shareholders held on June 7, 2018 .

  • Business Wire6 months ago

    Zymeworks Announces Pricing of Public Offering

    Zymeworks Inc. (NYSE/TSX:ZYME), a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, announced today the pricing of its previously- announced underwritten public offering (the “Offering”) of 5,400,000 common shares at a price to the public of US$15.75 per common share, for aggregate gross proceeds to the Company of approximately US$85.1 million, before deducting the underwriting discounts and commissions and estimated Offering expenses. In addition, the Company has also granted the underwriters of the Offering a 30-day over-allotment option to purchase up to an additional 810,000 common shares on the same terms and conditions.

  • Business Wire6 months ago

    Zymeworks Files Preliminary Prospectus Supplement for Offering of Common Shares

    Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, has today filed a preliminary prospectus supplement (the “Supplement”) to its short form base shelf prospectus dated May 24, 2018 (the “Base Prospectus”) in connection with an offering of its common shares (the “Offering”). The Supplement was filed with the securities regulatory authorities in each of the provinces and territories of Canada. The Supplement was also filed with the U.S. Securities and Exchange Commission (the “SEC”) as part of a registration statement on Form F-10, as amended (the “Registration Statement”), in accordance with the Multijurisdictional Disclosure System established between Canada and the United States.

  • Business Wire6 months ago

    Clinical Data for Zymeworks’ Novel Bispecific Antibody, ZW25, Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting

    Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, announced today the presentation of ZW25 clinical data by Funda Meric-Bernstam, MD, Principal Investigator for the ZW25 study at the University of Texas MD Anderson Cancer Center. Data from the ongoing multi-center Phase 1 study showed single agent ZW25 induced anti-tumor activity and was well tolerated in heavily pretreated patients across a range of HER2-expressing cancers.

  • Zymeworks and Daiichi Sankyo Expand Immuno-Oncology Collaboration Focused on Bispecific Antibodies
    Business Wire7 months ago

    Zymeworks and Daiichi Sankyo Expand Immuno-Oncology Collaboration Focused on Bispecific Antibodies

    Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional therapeutics, and Daiichi Sankyo Company, Limited announced today that they entered into a new license agreement, building upon their 2016 cross-licensing and collaboration agreement.